Yea Christopher 4
4 · KalVista Pharmaceuticals, Inc. · Filed Nov 26, 2025
Insider Transaction Report
Form 4
Yea Christopher
CHIEF DEVELOPMENT OFFICER
Transactions
- Exercise/Conversion
Common Stock
2025-11-21+3,750→ 224,714 total - Exercise/Conversion
Common Stock
2025-11-22+3,125→ 227,839 total - Sale
Common Stock
2025-11-24$13.45/sh−4,331$58,256→ 223,508 total - Exercise/Conversion
Restricted Stock Unit
2025-11-21−3,750→ 48,750 total→ Common Stock (3,750 underlying) - Exercise/Conversion
Restricted Stock Unit
2025-11-22−3,125→ 31,250 total→ Common Stock (3,125 underlying)
Footnotes (3)
- [F1]Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
- [F2]The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
- [F3]1/16th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date, subject to continued service through each vesting date.